Bms-907351

Bariatric Surgery

Universitaire Ziekenhuizen KU LeuvenActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 81/ 100

Competitive context

21 Active assets in the Bariatric Surgery cohort.

Asset / Sponsor	Phase	Rating
PROPOFOL Hospital dos Lusíadas	Phase 4	BB
RAMIFENTANYL Siirt Training and Research Hospital	Phase 4	B
CIS-DIAMMINEDICHLOROPLATINUM II University College Dublin	N/A	D
Cefazolin Hospital dos Lusíadas	N/A	D
Axitinib Universitaire Ziekenhuizen KU Leuven		D

View all 21 →

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant

BB

Indicative ·

70 / 100

castration-resistant prostate carcinomaDormant

BB

Indicative ·

70 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.